323 related articles for article (PubMed ID: 16052409)
1. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Takahashi T; Suzuki K; Ihara H; Mogami H; Kazui T; Urano T
Semin Thromb Hemost; 2005 Jun; 31(3):356-63. PubMed ID: 16052409
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
3. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
4. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1.
Kanse SM; Chavakis T; Al-Fakhri N; Hersemeyer K; Monard D; Preissner KT
J Cell Sci; 2004 Jan; 117(Pt 3):477-85. PubMed ID: 14679304
[TBL] [Abstract][Full Text] [Related]
6. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Praus M; Collen D; Gerard RD
Int J Cancer; 2002 Dec; 102(6):584-91. PubMed ID: 12447999
[TBL] [Abstract][Full Text] [Related]
7. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.
Carriero MV; Del Vecchio S; Capozzoli M; Franco P; Fontana L; Zannetti A; Botti G; D'Aiuto G; Salvatore M; Stoppelli MP
Cancer Res; 1999 Oct; 59(20):5307-14. PubMed ID: 10537314
[TBL] [Abstract][Full Text] [Related]
8. Effect of alpha3beta1 and alphavbeta3 integrin glycosylation on interaction of melanoma cells with vitronectin.
Janik ME; Przybyło M; Pocheć E; Pokrywka M; Lityńska A
Acta Biochim Pol; 2010; 57(1):55-61. PubMed ID: 20066177
[TBL] [Abstract][Full Text] [Related]
9. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma.
Ria R; Vacca A; Ribatti D; Di Raimondo F; Merchionne F; Dammacco F
Haematologica; 2002 Aug; 87(8):836-45. PubMed ID: 12161360
[TBL] [Abstract][Full Text] [Related]
10. Role of integrins in invasion of endometrial cancer cell lines.
Prifti S; Zourab Y; Koumouridis A; Bohlmann M; Strowitzki T; Rabe T
Gynecol Oncol; 2002 Jan; 84(1):12-20. PubMed ID: 11748970
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
12. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
Sugiura Y; Ma L; Sun B; Shimada H; Laug WE; Seeger RC; DeClerck YA
Cancer Res; 1999 Mar; 59(6):1327-36. PubMed ID: 10096567
[TBL] [Abstract][Full Text] [Related]
13. Divalent cations modulate the integrin-mediated malignant phenotype in pancreatic cancer cells.
Grzesiak JJ; Bouvet M
Cancer Sci; 2008 Aug; 99(8):1553-63. PubMed ID: 18754866
[TBL] [Abstract][Full Text] [Related]
14. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
15. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
[TBL] [Abstract][Full Text] [Related]
16. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
17. Potential role for insulin-like growth factor II and vitronectin in the endothelial-mesenchymal transition process.
Arciniegas E; Neves YC; Carrillo LM
Differentiation; 2006 Jul; 74(6):277-92. PubMed ID: 16831197
[TBL] [Abstract][Full Text] [Related]
18. Aspirin inhibits highly invasive prostate cancer cells.
Lloyd FP; Slivova V; Valachovicova T; Sliva D
Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.
Deng G; Curriden SA; Hu G; Czekay RP; Loskutoff DJ
J Cell Physiol; 2001 Oct; 189(1):23-33. PubMed ID: 11573201
[TBL] [Abstract][Full Text] [Related]
20. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
Stefansson S; Lawrence DA
Nature; 1996 Oct; 383(6599):441-3. PubMed ID: 8837777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]